Shots:
- Genovis to receive up front for an exclusive license to Xork & is eligible to receive development & sales-based milestones along with royalties on sales globally & holds the rights for research, preclinical, diagnostic & other non-therapeutic applications of Xork
- The collaboration will utilize Genovis’ IgG protease, IdeXork (Xork & Selecta’s ImmTOR platform for transformative gene therapies to treat patients with AAV immunity & IgG-mediated autoimmune diseases
- Selecta obtains an exclusive WW right to Xork. The combination of Xork & ImmTOR has the potential to mitigate pre-existing Abs to AAV, expand access to gene therapy, prevent de novo immunogenicity & enable re-dosing of Xork
Click here to read full press release/ article | Ref: Globe Newswire | Image: Selectabio
The post Selecta Enters into an Exclusive License Agreement with Genovis to Advance IgG Protease in Gene Therapy and Autoimmune Disease first appeared on PharmaShots.
